Lung Cancer

Mammalian Target of Rapamycin (mTOR) Inhibition in Advanced Bronchial Carcinoids

Nicola Fazio1 and Anna Maria Frezza2

1. Director; 2. Medical Oncologist, Unit of Medical Oncology Gastrointestinal and Neuroendocrine Tumors, European Institute of Oncology, Milan, Italy

Abstract
Bronchial carcinoids (BCs), comprising typical (TC) and atypical (AC) carcinoids, account for 1–2 % of all lung cancers and approximately 20–30 % of all neuroendocrine neoplasms (NENs). They represent the low- and intermediate-grade lung NENs, whereas small cell lung carcinoma (SCLC) and large cell neuroendocrine carcinoma (LCNEC) represent the high-grade entities. While the prognosis of BCs is favourable at early stages, it is poor when distant metastases are present. Unfortunately, there is a lack of therapeutic options as well as limited data to support the use of standard therapies and sequences of treatments. Some chemotherapeutic regimens have been reported to be active, but their efficacy has not been validated so far. Somatostatin analogues (SSAs) as single agents can be an option for very slow-growing disease, but their role in combination with other therapies has not been established. Among the new targeted agents, data from clinical trials showed that everolimus is a promising one.

Keywords
Lung NEN, lung neuroendocrine tumour, bronchial carcinoid, carcinoid tumour, pulmonary neuroendocrine neoplasm, somatostatin analogue, small cell lung cancer, large cell neuroendocrine carcinoma, bronchopulmonary carcinoid, everolimus

Neuroendocrine neoplasms (NENs) are a group of rare and heterogeneous malignancies that arise from neuroendocrine cells in most organs of the body. The presence, rather than absence of symptoms due to neuropeptides or hormones hypersecretion, distinguishes NENs in functioning and non-functioning tumours, respectively. The term NEN is used to denote any type of neuroendocrine malignancies, irrespective of histological grade and clinical behaviour.1 Gastroenteropancreatic (GEP) NENs are classified as neuroendocrine tumours (NETs) and neuroendocrine carcinomas (NECs).2 Thoracic NENs, the majority of which are bronchial, are classified as carcinoids and carcinomas (see Table 1).3–5 The terms ‘tumours’ for GEP and ‘carcinoids’ for lung represent the low/intermediate grade of malignant NENs.

Bronchial carcinoids (BCs), comprising typical (TC) and atypical (AC) carcinoids, account for 1–2 % of all lung cancers and approximately 20–30 % of all neuroendocrine neoplasms (NENs). They represent the low- and intermediate-grade lung NENs, whereas small cell lung carcinoma (SCLC) and large cell neuroendocrine carcinoma (LCNEC) represent the high-grade entities. While the prognosis of BCs is favourable at early stages, it is poor when distant metastases are present. Unfortunately, there is a lack of therapeutic options as well as limited data to support the use of standard therapies and sequences of treatments. Some chemotherapeutic regimens have been reported to be active, but their efficacy has not been validated so far. Somatostatin analogues (SSAs) as single agents can be an option for very slow-growing disease, but their role in combination with other therapies has not been established. Among the new targeted agents, data from clinical trials showed that everolimus is a promising one.6

BCs have a peak of incidence in the seventh decade.5,6 Data from the Surveillance, Epidemiology, and End Results (SEER) programme in the US suggests there is a growing incidence of BCs, with a fivefold increase reported between 1973 and 2004.6 This statistic could also be linked to an increased awareness and to the development of improved diagnostic techniques. More recent data from a Canadian population-based retrospective cohort study (n=5,619) found that between 1994 and 2009, the incidence of BCs and carcinoids for lung represent the low/intermediate grade of malignant NENs.

The prognosis of BCs varies according to sex, age group, socioeconomic status and tumour stage.6,11 In the Canadian study, BCs at an earlier stage
Mammalian Target of Rapamycin (mTOR) Inhibition in Advanced Bronchial Carcinoids

were associated with 59.7 % 5-year and 49.7 % 10-year survival.11 An Israeli multicentre study (n=142) reported 5-year survival rates for patients with TCs and ACs of 89 % and 75 %, respectively,12 while a European single-centre study (n=252,174 [69 %] with TC and 78 [31 %] with AC) of BCs reported a 5-year survival of 90 %.13 This variation in survival can be explained by different histological subtypes and disease stages in the various studies. TCs have a good prognosis since they have a low rate of recurrence after adequate resection, even if metastases in regional lymph nodes are present; a 5-year survival of 87–90 % has been reported.14–16 ACs are associated with a less-favourable prognosis and a 5-year survival of 44–78 %.16 However, distant metastases may occur many years after radical resection of the primary tumour. A 15-year follow-up is therefore recommended.17 Large-cell NEC has a poor prognosis with a 5-year survival of around 35 %,10–12 and LCNEC and SCLC have the worst prognosis.11,13–15 However, if we consider metastatic BCs, the median survival is 17 months and the associated 5-year survival rate is approximately 25 %.16

Table 1: Lung NENs Classification

<table>
<thead>
<tr>
<th>Histological Type</th>
<th>Necrosis</th>
<th>Mitotic Count</th>
<th>Tumour Differentiation</th>
<th>Grade of Malignancy</th>
</tr>
</thead>
<tbody>
<tr>
<td>TC</td>
<td>None</td>
<td>&lt;2/10 HPF</td>
<td>Well differentiated</td>
<td>Low</td>
</tr>
<tr>
<td>AC</td>
<td>Focal</td>
<td>2–9/10 HPF</td>
<td>Well differentiated</td>
<td>Intermediate</td>
</tr>
<tr>
<td>LCNEC</td>
<td>Extensive</td>
<td>&gt;9/10 HPF</td>
<td>Poorly differentiated</td>
<td>High</td>
</tr>
<tr>
<td>SCLC</td>
<td>Extensive</td>
<td>&gt;50/10 HPF</td>
<td>Poorly differentiated</td>
<td>High</td>
</tr>
</tbody>
</table>

While no antitumour treatment options were validated for metastatic BCs, several therapeutic options exist, none of which is currently approved, except for somatostatin analogues (SSAs) in functioning BCs. In addition to SSAs, chemotherapy, interferon (IFN), molecular targeted agents (MTAs) and peptide receptor radionuclide therapy (PRRT) may also be considered. The European Neuroendocrine Tumor Society (ENETS) recently published a consensus document with recommendations for best practice in BCs.7 There is no evidence supporting a specific sequence or priority for any of these therapies. In addition, liver-directed treatments, including embolisations (TAE, trans-arterial embolisation), radiofrequency (TARF, thermablation radiofrequency), and radioembolisation (TARE, trans-arterial radioembolisation) can be useful.18–20 Mammalian target of rapamycin inhibitors (mTORI) have been widely investigated in NETs and everolimus has been approved for the treatment of patients with progressive neuroendocrine tumours of pancreatic origin (PNET) that are unresectable, locally advanced or metastatic. This review aims to discuss the role of the mTOR pathway in the pathogenesis of BCs, as also preclinical and clinical evidence supporting the use of mTOR-I is in this disease.

The Role of mTOR Signal Pathway in Bronchial Carcinoids

The mTOR Signal Pathway

mTOR is an intracellular serine/threonine kinase acting as a key regulator in cell survival, proliferation and apoptosis. Its interaction with multiple partners leads to the formation of two multi-protein complexes named mTOR complex 1 (mTORC1) and 2 (mTORC2). mTORC1 consists of mTOR, the regulatory-associated protein of mTOR (RAPTOR) and the target of rapamycin complex subunit LST8. mTORC1 is activated by multiple extracellular growth factors via the phosphatidylinositol 3-kinase (PI3K)/AKT pathway, and it plays a key role in modulating cellular proliferation through the interaction with its downstream targets, including the eukaryotic translation initiation factor 4E binding protein-1 (4EBP-1) and ribosomal S6 kinase-1 (S6K1).21 Conversely, the association of mTOR with target of rapamycin complex subunit LST8, rapamycin-insensitive companion of mTOR (RICTOR) and mitogen-activated protein kinase-associated protein-1 forms mTORC2. Although its role is still poorly understood, mTORC2 is known to directly phosphorylate protein kinase B (AKT) in the PI3K pathway. S6K1 from mTORC1 inhibits the PI3K/AKT pathway via suppression of insulin receptor substrate-1 (IRS-1); thus, the mTORC1/mTORC2 complex is both an upstream and downstream regulator of cellular function, and

IGFR-1 = insulin-like growth factor receptor-1; IRS = insulin receptor substrate; mTOR = mammalian target of rapamycin; mTORC1 = mTOR complex; PI3K = phosphatidylinositol 3-kinase.

regulates cell survival, cytoskeletal remodelling and cell migration (see Figure 1).21,22 Binding of insulin or insulin-like growth factors (IGFs) to their receptors leads recruitment of PI3K to the cell membrane, activating AKT (protein kinase B). Phosphatase and tensin homologue (PTEN) is an inhibitory regulator of the PI3K/AKT/mTOR pathway that antagonises the action of PI3K.

Activation of mTOR contributes to the pathogenesis of many tumour types, and several findings have suggested that the mTOR pathway plays a key role in the development of NENs. Improved understanding of molecular genetics has shown that NENs are common in familial cancer syndromes arising from mutations in genes encoding proteins that lie upstream from mTOR.23 Moreover, a study performing exome sequencing reported somatic mutations in genes involved in the mTOR pathway in 14 % of sporadic pancreatic NETs.24

The mTOR Pathway in Bronchial Carcinoids

The proven efficacy of everolimus and the identification of multiple germline and somatic mutations in the PI3K/AKT/mTOR genes in pNETs highlight the relevance of this pathway in human endocrine tumours, leading to the exploration of its possible role in BCs. The first evidence of activated mTOR pathway in lung NENs came from a large Italian multicentric series of 218 surgically resected lung NENs patients, including both low- to intermediate-grade and high-grade tumours. The authors reported a differential activation of the mTOR pathway in the spectrum of lung NENs, with higher levels of phospho-mTOR (p-mTOR) and p-S6K expression by immunohistochemistry (p<0.001) in the low- to intermediate-grade tumours compared with the high-grade group.
Figure 2: Resistance to mTOR Inhibitors

In 2010, Zatelli et al. observed an anti-proliferative effect of everolimus in human BC tumour cells associated with a reduction in chromogranin A level, VEGF secretion and cell viability, probably mediated by a mechanism involving IGF1 signalling. 15 mTOR expression levels together with aggressive clinical features (i.e. AC, larger tumour size, higher number of mitoses) were found to be associated with an enhanced sensitivity to everolimus. Of note, previous reports showed that SSAs, such as pasireotide, were also associated with a decrease in VEGF expression and circulating IGF1 level, suggesting that a combined treatment approach might improve the outcome through an additive or synergistic effect. 22 The same group confirmed everolimus activity on BC primary cultures and found a correlation between viability reduction and apoptosis activation. 22

Molecular Bases for mTOR Inhibitor Resistance

Attempts have been made to clarify the molecular bases of resistance to treatment with mTOR-Is and identify possible strategies to overcome this limitation. Although everolimus resistance is not yet completely understood, two potential mechanisms have been proposed: AKT activation by means of mTORC-2, and IGF1-IGF receptor (IGFR) pathway activation by means of phosphorylated S6K1 (see Figure 2). 22,23 As previously stated, everolimus is selective for mTORC-1 alone and also inhibits the downstream molecule S6K1. The latter normally exerts a negative feedback on the PI3K/AKT/mTOR pathway activated by growth factors. Therefore, inhibiting S6K1 can reactivate mTOR, leading to everolimus resistance. 24

A possible approach to overcome mTOR-Is resistance is the use of multi-targeted inhibitors. NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K and mTOR signalling activation and inhibits the growth of cancer cells with activating PI3K mutations. 26 NVP-BEZ2235 activity has been reported in BCs cell lines. 22,23 A study in everolimus-resistant human BC tissues found that NVP-BEZ2235 is twice as potent as everolimus in reducing cell viability and activating apoptosis in BC tissues sensitive to mTOR inhibitors, but no activity was reported in everolimus-resistant BC tissues and cell lines, suggesting that different pathways might be involved in resistance to mTOR-Is in BCs. 24 Conversely, a preclinical study performed in PNET cells similarly showed that NVP-BEZ2235 exerts a stronger anti-proliferative activity compared with everolimus, but reported that the combined administration of the two inhibitors exhibit a synergic effect, with activity also reported in everolimus-resistant cells. 25

Clinical Evidence Supporting the Use of Everolimus in Bronchial Carcinoids

Clinical Evidence of Everolimus as a Single Agent in Bronchial Carcinoids

Preclinical Studies of mTOR Inhibitors in Bronchial Carcinoids

Preclinical Evidence of Activity

The availability of data suggesting the involvement of mTOR signal pathway in BCs has led to studies investigating the activity of mTOR-Is in this setting, mTOR-Is, including rapamycin and its analogues, temsirolimus, everolimus and ridaforolimus, exert their activity in cancer by interacting with the FK506 binding protein and generating a complex that binds to mTORC1, inhibiting downstream signalling (see Figure 1). 24

In 2010, Zatelli et al. observed an anti-proliferative effect of everolimus in human BC tumour cells associated with a reduction in chromogranin A level, VEGF secretion and cell viability, probably mediated by a mechanism involving IGF1 signalling. 15 mTOR expression levels together with aggressive clinical features (i.e. AC, larger tumour size, higher number of mitoses) were found to be associated with an enhanced sensitivity to everolimus. Of note, previous reports showed that SSAs, such as pasireotide, were also associated with a decrease in VEGF expression and circulating IGF1 level, suggesting that a combined treatment approach might improve the outcome through an additive or synergistic effect. 22 The same group confirmed everolimus activity on BC primary cultures and found a correlation between viability reduction and apoptosis activation. 22
Mammalian Target of Rapamycin (mTOR) Inhibition in Advanced Bronchial Carcinoids

Table 2: Summary of Clinical Trials with Everolimus that Incorporated Thoracic Carcinoids

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Trial</th>
<th>N (BCs)</th>
<th>Study Type</th>
<th>Overall Results</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>E + O LAR</td>
<td>US multicentric</td>
<td>60 (4)</td>
<td>Phase II</td>
<td>PR in 22 %, SD in 70 %, PO in 8 %; OS not reached</td>
<td>Yao et al., 2008,41</td>
</tr>
<tr>
<td>E + O LAR</td>
<td>Italian multicentric</td>
<td>50 (11)</td>
<td>Phase II, first line</td>
<td>ORR 18 %; 2 % of patients had a CR, 16 % a PR and 74 % SD; median TTP and OS not reached</td>
<td>Bajetta et al., 2014,42</td>
</tr>
<tr>
<td>E + O LAR versus PLB + O LAR</td>
<td>RADIANT-2, intercontinental</td>
<td>425 (44)</td>
<td>Randomised phase III</td>
<td>Median PFS was 16.4 (95 % CI 13.7–21.2) months in the E + O LAR group versus 11.3 (8.4–14.6) months in the PLB plus O LAR group (HR 0.77, 95 % CI 0.59–1.00; one-sided p&lt;0.026)</td>
<td>Pavel et al., 2011,43</td>
</tr>
<tr>
<td>E + O LAR versus PLB + O LAR</td>
<td>RADIANT-2, intercontinental, lungNET subgroup analysis</td>
<td>44 (44)</td>
<td>Randomised phase III, post hoc analysis</td>
<td>Median PFS was 13.63 months in the E + O LAR arm versus 5.59 months in the PLB + O LAR arm (relative risk for progression: HR 0.72; 95 % CI 0.31–1.68; p=0.228)</td>
<td>Fazio et al., 2013,44</td>
</tr>
<tr>
<td>E alone</td>
<td>European multicentric</td>
<td>73 (22)</td>
<td>Phase II</td>
<td>By local review, 5 % had a PR, with SD in 65 % patients; median PFS by central review was 185 days (95 % CI 158–253); median PFS by local investigator review was 285 days (95 % CI 231 – not estimable)</td>
<td>Pavel et al., 2012,45</td>
</tr>
<tr>
<td>E versus PLB</td>
<td>RADIANT-4, global trial</td>
<td>302 (90)</td>
<td>Randomised phase III</td>
<td>Median PFS was 11.0 months (95 % CI 9.2–13.3) in the E arm versus 3.9 months (95 % CI 3.6–7.4) in the PLB arm (HR 0.48, 95 % CI 0.35–0.67; p=0.001)</td>
<td>Yao et al., 2015,46</td>
</tr>
<tr>
<td>E versus PAS versus E/PAS</td>
<td>LUNA, intercontinental</td>
<td>121 (121)</td>
<td>Randomised phase II</td>
<td>Ongoing</td>
<td>Not yet presented</td>
</tr>
</tbody>
</table>

AE = adverse event; BCs = bronchial carcinoids; CI = confidence interval; CR = complete response; E = everolimus; HR = hazard ratio; LAR = long-acting repeatable; O = octreotide; ORR = overall response rate; OS = overall survival; PAS = pasireotide; PD = progressive disease; PFS = progression-free survival; PLB = placebo; PR = partial response; SD = stable disease; TTP = time-to-progression.

The everolimus/octetotide LAR combination was studied in RADIANT-2, an international, randomised, double-blind Phase II trial (n=60) comparing everolimus plus octreotide LAR versus placebo plus octreotide LAR in NETs from different primary sites with carcinoid syndrome.46 Although according to a central radiology review, the combined therapeutic regimen resulted in an improvement in PFS (16.4 months, 95 % CI 13.7–21.2) in the everolimus plus octreotide LAR group and 11.3 (8.4–14.6) months in the placebo plus octreotide LAR group (HR 0.77, 95 % CI 0.59–1.00; p=0.026), this was not statistically significant considering the pre-specified p value of 0.024. A subgroup analysis of the RADIANT-2 trial indicates that patients with advanced lung NET (n=44), everolimus plus octreotide LAR improved median PFS by 2.4-fold; in particular, PFS was 13.63 months in the everolimus plus label phase II trial (95 % CI 5.55–14.29) compared with 5.59 months in the placebo plus octreotide LAR arm (95 % CI 2.79–27.76) (see Table 2). Everolimus plus octreotide LAR was also associated with a 28 % reduction in the estimated risk for progression (HR 0.72, 95 % CI 0.31–1.68; p=0.228). Although not statistically significant this was a clinically meaningful improvement in PFS, better than the benefit seen in the overall RADIANT-2 population (a PFS increase of 5 months). The most frequently reported treatment-emergent AEs included stomatitis (69 % versus 0.0 %), rash (33.3 % versus 0.0 %), diarrhea (27.3 % versus 0.0 %) and asthenia (24.2 % versus 9.1 %). These were similar to AEs reported in the overall RADIANT-2 population and consistent with the known safety profiles of everolimus and octreotide LAR.46 However, it should be noted that this is a small retrospective analysis with imbalanced patient numbers between groups; the RADIANT-2 study did not stratify based on the primary tumour site, therefore there were more patients with BC in the everolimus plus octreotide LAR arm (33 patients) than in the placebo plus octreotide arm (11 patients).47

Recently, a phase II study (n=50, 11 had BCs) found that the everolimus/octetotide LAR combination was active and well tolerated in treatment-naïve patients with advanced NETs from different sites. The overall response rate (CR) was 18 %; 2 % of patients had a complete response (CR), 16 % a partial response (PR) and 74 % stable disease (SD). At a median follow-up of 277 days, median time to progression and overall survival were not reached.48

The everolimus/SSA combination is currently being investigated in lung NET within the multicentric international LUNA trial; this is a prospective phase II three-arm study comparing pasireotide LAR, everolimus alone and the combination of pasireotide LAR and everolimus, and it is the first study focused on BCs selectively. Pasireotide is a novel SSA that binds to a broader range (sstr-1,2,3,5) of somatostatin receptor subtypes than octreotide (see Figure 3).49 A phase I study has established the feasibility...
of combining pasireotide LAR and everolimus.46 The recruitment of the LUNA trial has been concluded sooner than expected with the inclusion of 120 patients with advanced metastatic BCs underlying the unmet need of therapeutic options in this disease. Results are awaited (see Table 2).47

In addition, the combined inhibition of mTOR and epidermal growth factor receptor (EGFR) has been shown to give synergistic effects in several cancer therapies, and a preclinical study suggested that this approach could be promising in the treatment of BCs.48 This is currently being investigated in a phase II clinical trial.49

Summary and Concluding Remarks

BCs represent a substantial proportion of NENs and given the lack of standard antitumour therapies there is a concrete need for effective therapeutic options. A considerable body of preclinical and clinical data suggests that mTOR-Is, specifically everolimus, are safe and efficacious in the treatment of BCs. A sub-analysis of the RADIANT-2 study suggested that the combination of everolimus and octreotide BCs could be beneficial in patients with advanced low- to intermediate-grade (unresectable or metastatic) functioning BCs. Although these results were not statistically significant and the study arms had an unbalanced distribution due to the lack of stratification for the lung primary site, this is an important finding. Following the recently presented data from the RADIANT-4 trial, including 30% of patients with BCs in the study population, everolimus appears to be a promising therapeutic option for non-functioning advanced BCs. An ongoing clinical trial focused on BCs (the LUNA trial) will hopefully provide more information about everolimus as single agent and its combination with pasireotide in this rare condition.

17. Greulsing-Glaubiger S, Franz S, Teng M, et al., Octreotide and the mTOR inhibitor RAD001 (everolimus) block proliferation and interact with the Akt-mTOR-P70S6K pathway in a neuro-endocrine tumour cell line, Neuroendocrinology, 2008;87:168–81.